Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease
- 24 August 2013
- journal article
- review article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 18 (2), 265-268
- https://doi.org/10.1007/s10157-013-0847-z
Abstract
Advanced chronic kidney disease (CKD) results in a constellation of dysregulation of lipid metabolism, oxidative stress, and inflammation which are causally interconnected and participate in a vicious cycle. The CKD-associated lipid disorders are marked by impaired clearance of very low density lipoprotein and chylomicrons, hypertriglyceridemia, formation of small dense low-density lipoprotein (LDL), oxidative modification of LDL, intermediate density lipoprotein and chylomicron remnants, and high-density lipoprotein deficiency and dysfunction. This review provides a brief overview of the role of CKD-induced lipid disorders in the pathogenesis of oxidative stress, inflammation, cardiovascular disease, impaired exercise capacity, cachexia and wasting syndrome.Keywords
This publication has 48 references indexed in Scilit:
- Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I productionTranslational Research, 2013
- Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expressionClinical and Experimental Nephrology, 2011
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Excerpts From the US Renal Data System 2009 Annual Data ReportAmerican Journal of Kidney Diseases, 2010
- In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptideKidney International, 2009
- Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidneyAmerican Journal of Physiology-Renal Physiology, 2009
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Reverse Cholesterol Transport Pathway in Experimental Chronic Renal FailureAmerican Journal of Nephrology, 2009
- Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD)Nephrology Dialysis Transplantation, 2009
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004